A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson's disease, in healthy volunteers.

Drug Des Devel Ther · 2019 · PMC6445238 · PMID 30992659

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

In the SAD study for the first two dose cohorts (10 mg and 30 mg KM-819), an increasing trend of bilirubin levels was apparent on day 2, with bilirubin levels returning to normal on day 7.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.